All Activity

These issues “present serious risks to public safety, market integrity and the tax revenue framework that supports Colorado’s regulated cannabis industry.” By Christopher Osher, ProPublica and Evan Wyloge, The Denver Gazette This story was originally published by ProPublica. Colorado regulators announced on Monday that they plan to crack down on companies that illegally sell cheaper and potentially hazardous hemp products as marijuana. The state’s Marijuana Enforcement Division said it had detected “regulatory compliance issues” that threaten to unravel the marijuana industry in the nation’s first legal retail market. These issues “present serious risks to public safety, market integrity and the tax revenue framework that supports Colorado’s regulated cannabis industry,” the agency stated in an industry bulletin. A Denver Gazette and ProPublica investigation in January reported that, despite Colorado being one of the first states to ban the sale of intoxicating hemp products, the legislature and regulators failed to adopt many regulations that other states have employed to keep hemp products off marijuana dispensary shelves. Creating the liquid distillate for vapes and edibles from hemp is much cheaper than using marijuana, giving companies a competitive advantage. But regulators say they’re worried because manufacturers rely on toxic and potentially hazardous chemicals to convert the nonintoxicating compound CBD that is prevalent in hemp into THC, the psychoactive compound that makes people feel high. Regulators have banned such chemical synthesis because they say they fear chemical residues could remain in finished products, imperiling consumers. Colorado manufacturers have exploited gaps in the state’s testing and enforcement system to continue using hemp to make products marketed as marijuana, even though doing so is against state law, according to regulatory investigations, previous agency bulletins and testimony and lab results contained in several lawsuits. In 2024, state investigators found that one popular brand of marijuana vapes sold in dispensaries was not only derived from hemp, but also contaminated with methylene chloride, a chemical often used to convert CBD from hemp into THC. It is prohibited by Colorado’s marijuana regulators and banned for most uses by the U.S. Environmental Protection Agency because it can cause liver and lung cancer and damage the nervous, immune and reproductive systems. Ware Hause, the company that manufactured those vapes, surrendered its marijuana license in response to the investigation. Ware Hause’s owner, Thanh Hau, and the company’s lawyer have declined to comment. Congress passed a law last November banning nearly all intoxicating hemp products throughout the country starting this fall, but it’s unclear how the government will implement that ban, and hemp manufacturers are pushing to overturn it. In December, President Donald Trump issued an executive order telling his aides to work with Congress on developing regulations that could allow some hemp products. Colorado’s Marijuana Enforcement Division announced in the Monday bulletin that agency officials had “identified and investigated evidence” indicating marijuana businesses are using illicit practices and banned methods to manufacture products instead of relying on marijuana, which is supposed to be tracked for safety. The Colorado Hemp Association and the Colorado Hemp Education Association did not immediately respond to requests for comment. Beyond the safety issues, the bulletin also noted that some marijuana manufacturers and cultivators are avoiding marijuana tax obligations through “a pattern of noncompliance” in the sales transactions they report to the state’s “seed-to-sale” tracking system, which follows marijuana from initial planting to the sale of pot, vapes and other products in dispensaries. Companies are misreporting their bulk marijuana sales at nominal prices, in some cases as low as $1 a pound for unprocessed marijuana material, the bulletin stated. Those products typically fetch as much as $600 a pound on the open market, depending on the category of marijuana, according to industry insiders. Such fraudulent reporting has robbed the state and local governments of millions of dollars in marijuana tax revenue, industry insiders say, though there’s no official estimate. The agency said it would pursue emergency rules to address such problems. Suspicious and anomalous transactions and inventories the state detects will prompt investigations, the bulletin stressed. Companies caught using hemp or other illicit material they pass off as marijuana face “immediate product embargo, license suspension or revocation, significant monetary penalties and referral to law enforcement,” the regulators warned. The Denver Gazette and ProPublica have attempted to track anomalous transactions, but the Marijuana Enforcement Division has maintained that the sales transaction records, even those that don’t identify companies, are not public. Marijuana industry representatives met with division regulators late last month to press for a more aggressive response to hemp substitution from the agency, even though it could affect some companies in the industry. The representatives argued that bad actors are unfairly driving down prices and shifting the tax burden to manufacturers and cultivators who are trying to follow the rules. The bulletin was released a couple of weeks after that meeting. “The division is also exploring additional modifications to its testing and screening protocols to detect” illicit products and banned methods, and it may require additional lab testing “of products throughout the supply chain as needed,” the agency’s bulletin stated. This article was produced for ProPublica’s Local Reporting Network in partnership with The Denver Gazette. Sign up for Dispatches to get stories in your inbox every week. Photo courtesy of WeedPornDaily. The post Colorado Marijuana Officials Announce Crackdown On Sales Of Hemp Products Amid ‘Risks To Public Safety’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

President Donald Trump on Saturday appeared to complain that federal officials are “slow-walking” following through on an executive order he issued to complete the process of federally rescheduling marijuana. “You’re going to get the rescheduling done, right, please? Will you get the rescheduling done, please?” Trump said, seeming to speak to a Department of Justice official during an event in the Oval Office on Saturday. “You know, they’re slow-walking me on rescheduling. You’re going to get it done, right?” The president did not specifically mention cannabis, and it’s not immediately clear who the official he was speaking to is, but it has been four months since he directed the attorney general to complete the process of moving marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III “in the most expeditious manner.” That hasn’t yet occurred, however. The president’s comments came during a signing ceremony for a new executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics, a move aimed at making substances such as psilocybin, ibogaine, LSD and MDMA more readily available to patients in clinical settings. Longtime Trump advisor Roger Stone recently said someone in the Trump administration is “holding up” the completion of the cannabis rescheduling proposal. Trump this month fired Attorney General Pam Bondi, who opposed marijuana reform in Florida when she was that state’s attorney general, although there is no indication that cannabis was at the center of the president’s frustration with her performance in his administration. Todd Blanche, who previously served as Trump’s personal attorney and as deputy attorney general, is serving as acting attorney general until Bondi’s replacement is confirmed for the position. During his Senate Judiciary Committee confirmation process, Blanche said in response to a written question about marijuana rescheduling that he would “give the matter careful consideration after conferring with all relevant stakeholders, including [Drug Enforcement Administration] personnel.” When asked about aligning federal and state marijuana laws, he said that “coordination between federal and state authorities is critically important” but that he had “not had the opportunity to study this particular issue.” “If confirmed, I will consult with the necessary stakeholders and give this matter careful consideration,” he said. The post Trump Complains DOJ Is ‘Slow-Walking’ Marijuana Rescheduling, Four Months After He Issued An Order To Get It Done appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

President Donald Trump has signed an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics, a move aimed at making substances such as psilocybin, ibogaine, LSD and MDMA more readily available to patients in clinical settings. The move will “dramatically accelerate access to new medical research and treatments based on psychedelic drugs,” Trump said. The order, which the president signed in the Oval Office on Saturday alongside federal health officials, advocates and the podcaster Joe Rogan, directs the Food and Drug Administration (FDA) to issue new guidance for researchers on conducting clinical trials on psychedelics. “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression—including our cherished veterans,” Trump said. Steps taken under the order will “clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that become FDA approved,” the president said. Some psychedelics like psilocybin and MDMA have been designated with “breakthrough therapy” status, meaning that preliminary clinical evidence shows they can provide substantial improvement over existing therapies. Trump said his order will “expedite” the further review of such substances. Trump also announced that the federal government is making $50 million available to support state-level research on ibogaine and is “opening a pathway for the substance to be administered to desperately ill patients under the Right to Try law” that he signed during his first term in office. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. said at the signing event that under the president’s order his department “will accelerate research, approval and access to new mental health treatments, including psychedelic therapies.” “We’re taking this decision, this decisive step, to confront one of the most urgent public health challenges facing our nation, the mental health crisis,” he said. “This executive order will remove legal impediments that block American researchers, scientists, physicians and clinicians from properly studying these medicines and, where appropriate, establishing protocols for their safe therapeutic use.” Thanks to the leadership of President Trump, under this historic Executive Order, @HHSGov will accelerate research, approval, and access to new mental health treatments, including psychedelic therapies such as ibogaine. pic.twitter.com/ZiUl5IaoBL — Secretary Kennedy (@SecKennedy) April 18, 2026 Kennedy also said health officials will coordinate with the Drug Enforcement Administration (DEA) and Department of Justice on “rescheduling reviews after successful Phase 3 trials” on psychedelics. The order says that “the Attorney General shall, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act.” Food and Drug Administration Commissioner Marty Makary said that his agency will issue three national priority vouchers for psychedelics. “Under this new program in this administration, drugs can get approved in weeks—not a year or a year plus, but in weeks—if they are in line with our national priorities,” he said. Makary also announced “the first ibogaine investigational new drug clearance,” which he said will “pave the way for the first-ever human trials in the United States” on the psychedelic. HHS is confronting the mental health crisis: @US_FDA will prioritize therapies that have received Breakthrough Therapy designation Expanding the use of Right to Try Coordinate with the @DEAHQ and @TheJusticeDept to begin rescheduling reviews after successful Phase 3… pic.twitter.com/G4wKePKyd5 — HHS Rapid Response (@HHSResponse) April 18, 2026 Rep. Morgan Luttrell (R-TX), who also attended the signing ceremony, said in a statement that he “can personally attest to the significant benefits of this treatment.” “It changed my life, and I look forward to seeing the impact it will have on countless others,” he said. “We’re losing too many veterans. If this treatment gives us a chance to change that, then we owe it to them to pursue it. The President’s executive order brings us closer to a lasting solution that our veterans deserve.” Centers for Medicare & Medicaid Services Director Mehmet Oz called the president’s action “a paradigm shift for mental health treatment.” “Grateful to work alongside leaders who refuse to accept ‘no’ when lives are on the line,” he said. In a paradigm shift for mental health treatment, President Trump’s Executive Order fast-tracks access to psychedelic treatments for 14 million Americans in need. Momentum matters—credit to @joerogan for reigniting the conversation and to @SecKennedy for driving a… pic.twitter.com/ok0DnAcotV — Dr. Mehmet Oz (@DrOz) April 18, 2026 A growing body of research and experience indicates that psychedelics can help people suffering with post-traumatic stress disorder, traumatic brain injuries, drug addiction and other mental health disorders. Lawmakers in a number of states have passed legislation to support clinical trials with the aim of developing ibogaine into a legal medication with approval from the Food and Drug Administration (FDA). Texas officials, for example, recently announced that the state will move ahead with launching its own research program on the psychedelic after the they couldn’t find a company to lead a consortium on the issue under a bill enacted last year. The federal psychedelics move comes four months after Trump issued an executive order directing the Department of Justice to completed the process of moving marijuana from Schedule I of the CSA to Schedule III “in the most expeditious manner”—though that still hasn’t happened. Accelerating Medical Treatments for Serious Mental Illness@JoeRogan: "For 56 years we've lived under those terrible conditions. We're free of that now. Thanks to all these people… and thanks to President Trump." https://t.co/j1tkGACSM7 pic.twitter.com/aQmZl3z4PG — The White House (@WhiteHouse) April 18, 2026 Meanwhile, Kennedy said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.” In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.” “Everybody in my agency…is very anxious to get a rule out there that will allow these kind of studies and will allow access under therapeutic settings, particularly [for] the military soldiers who have suffered these injuries to get access to these products,” the HHS secretary said. “We’re working through that process now. We’re all working on it and trying to make it happen.” “I think that we’re going to get it done,” he said. Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” Veterans Affairs Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access. Thank you, President Trump. We need an all-of-the-above strategy when it comes to tackling mental health, and your EO opens up new possibilities for America’s Veterans. https://t.co/OOqKuWd6C2 — VA Secretary Doug Collins (@SecVetAffairs) April 18, 2026 Bipartisan congressional lawmakers introduced legislation this session to provide $30 million in funding annually to establish psychedelic-focused “centers for excellence” at U.S. Department of Veterans Affairs (VA) facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine. Former U.S. House Speaker Newt Gingrich (R-GA) has said ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options. The post Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental Health Conditions appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The judge here is concerned about retailers that have made big investments in inventory, and they can’t move it, they can’t transport it, they can’t sell it.” By Megan Henry, Ohio Capital Journal A Franklin County judge granted a temporary restraining order (TRO) to allow two smoke shops to sell off their products less than a month after Ohio Senate Bill 56 took effect, which bans low-level THC hemp products and changes the state’s marijuana laws. Franklin County Court of Common Pleas Judge Jeffrey M. Brown issued a TRO Thursday allowing Happy Harvest locations and Get Wright Lounge to sell their existing products. Happy Harvest has locations in Delaware, Marion and Wood counties. Get Wright Lounge has one location in Columbus. “The judge here is concerned about retailers that have made big investments in inventory, and they can’t move it, they can’t transport it, they can’t sell it,” said Scott Pullins, the attorney for the plaintiffs. “He’s given them, really, a grace period that the legislature should give them.” Ohio S.B. 56 took effect March 20 after Ohioans for Cannabis Choice failed to get enough signatures to get a referendum on the November ballot for voters to block the law. Under the new law, THC levels in adult-use marijuana extracts will be reduced from a maximum of 90 percent down to a maximum of 70 percent, cap THC levels in adult-use flower to 35 percent, and prohibit smoking in most public places. The two businesses will only be able to sell products to people 21 and older, according to the Franklin County TRO. “Products obviously cannot resemble candy or anything along those lines,” Pullins said. He was not sure how much stock the stores had left. “If you haven’t gotten it out of state before the law goes into effect, you’re kind of stuck,” Pullins said. “You get caught transporting it, and they’re going to charge you with felony drug trafficking.” The new law prohibits possessing marijuana in anything outside of its original packaging, criminalizes bringing legal marijuana from another state back to Ohio, and requires drivers to store marijuana in the trunk of their car while driving. A preliminary injunction hearing will be scheduled in about two weeks, Pullins said. “We’ll come in and bring witnesses in, but we think we have a good shot at least being able to continue in business through November,” he said. New federal restrictions on hemp products are set to take effect November 12. Congress voted last November to ban products that contain 0.4 milligrams of total THC per container when they voted to reopen the government. Previously, the 2018 Farm Bill said hemp can be grown legally if it contains less than 0.3 percent THC. Ohio state Rep. Jennifer Gross, R-West Chester, recently joined the lawsuit as a plaintiff. She voted against Senate Bill 56 in November. “[She’s] someone that can testify to the legislative process, how it was handled,” Pullins said. “She’s been very supportive throughout the process.” A Sandusky County judge recently issued TRO on the hemp portion of the new law which allows the sale of intoxicating hemp products to continue in Fremont. This story was first published by Ohio Capital Journal. The post Ohio Judge Temporarily Pauses Hemp Product Ban For Two Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Our agency focuses on making the process simple and stress-free. When exploring Escorts Subhash Nagar, we advise clients to take their time and choose wisely. This ensures better compatibility and creates a more natural and enjoyable connection.

i love reading this article so beautiful!!great job! 오피스타

You know your projects stand out of the herd. There is something special about them. It seems to me all of them are really brilliant! 오피스타

Its a great pleasure reading your post.Its full of information I am looking for and I love to post a comment that "The content of your post is awesome" Great work. 오피스타 I recently came across your blog and have been reading along. I thought I would leave my first comment. I don't know what to say except that I have enjoyed reading. Nice blog. I will keep visiting this blog very often. THCA Flower

With continuous breakthroughs in cutting-edge technologies such as bio-based materials, 3D printing, and intelligent recycling, the green transformation path of the flat chested sex doll will become increasingly wider. For consumers, choosing flat chested sex dolls is not only embracing an aesthetic attitude but also voting for a more sustainable and inclusive future through their consumption.

Using medical marijuana appears to help people reduce the use of other medications, including opioids, sleeping aids and antidepressants, according to a new study involving more than 3,500 patients. They also experience far fewer negative side effects after switching to cannabis from prescription drugs. The results of the survey show that across all medication categories, patients were able to reduce use of other prescription drugs by an average of 84.5 percent after beginning medical cannabis consumption. More than half the patients (58.9 percent) stopped use of other prescription medications completely. The study, conducted and published by the medical cannabis and telehealth company Bloomwell, involved an online survey of 3,528 patients in Germany last month. “Through the use of medical cannabis, patients were able to reduce the use of other prescription medications by an average of 84.5% across all categories.” It found that 93.4 percent of patients taking prescription sleeping pills were able to reduce their use by at least half after starting medical marijuana, and 75.5 percent were able to quit taking the meds completely. For methylphenidate, an ADHD medication sold under the name Ritalin, 77.3 percent of medical marijuana patients were able to stop completely. Sixty-one percent of patients who previously relied on opioids were able to completely discontinue their use with the help of medical marijuana. Ceasing to use the prescription drugs also led to a large reduction in medication-associated side effects, with 60.7 percent reporting they were no longer experiencing any. “These patient reports prove that in many cases, besides the actual symptom treatment, one of the essential reasons for an individual therapeutic trial with medical cannabis is the absence or reduction of medication-associated side effects,” the study concluded. “60.7% of patients report no longer experiencing medication-associated side effects due to the use of medical cannabis.” There were positive side effects reported, however, with 67.8 percent saying medical cannabis helped them concentrate better, 61.9 percent saying it helped them foster more social contacts and 53.9 percent experiencing fewer sick days off from work. “The main reason for prescribing medical cannabis, besides symptom treatment, is the reduction or avoidance of side effects from other medications,” Julian Wichmann, co-Founder and CEO of Bloomwell, said in a press release. “For example, anyone who can completely discontinue opioids by using medical cannabis has a good chance of managing their daily life and work free of side effects.” “We should therefore not demand restrictions on access to medical cannabis, but rather ensure that doctors are more willing to attempt an individual therapeutic trial with medical cannabis, or at least recommend it and refer patients to colleagues,” he said. “At the same time, our survey shows that we should finally discuss the great benefits of medical cannabis more openly, instead of exclusively warning about empirically unproven risks and discrediting flowers.” This is not the first study to position medical cannabis as a safer alternative to opioids and other prescription drugs. About one in three Americans who use CBD say they take it as an alternative or supplement to at least one medication—particularly painkillers—according to a federally funded study published in February. Similarly, another recent federally funded study, published by the American Medical Association (AMA), added more evidence that marijuana can serve as an effective substitute for opioids in chronic pain treatment. Other AMA-published research has found that legalizing marijuana for medical or recreational purposes is “significantly associated with reduced opioid use among patients diagnosed with cancer.” A separate paper published in October similarly found that medical marijuana legalization is “associated with significant reductions in opioid prescribing.” In August, meanwhile, Australian researchers published a study showing that marijuana can serve as an effective substitute for opioids in pain management treatment. Another study published last year in the journal Drug and Alcohol Review found that, among drug users who experience chronic pain, daily cannabis use was linked to a higher likelihood of quitting the use of opioids—especially among men. Other research also found that legalizing medical cannabis appeared to significantly reduce monetary payments from opioid manufacturers to doctors who specialize in pain, with authors finding “evidence that this decrease is due to medical marijuana becoming available as a substitute” for prescription painkillers. Other recent research also showed a decline in fatal opioid overdoses in jurisdictions where marijuana was legalized for adults. That study found a “consistent negative relationship” between legalization and fatal overdoses, with more significant effects in states that legalized cannabis earlier in the opioid crisis. Authors estimated that recreational marijuana legalization “is associated with a decrease of approximately 3.5 deaths per 100,000 individuals.” “Our findings suggest that broadening recreational marijuana access could help address the opioid epidemic,” that report said. “Previous research largely indicates that marijuana (primarily for medical use) can reduce opioid prescriptions, and we find it may also successfully reduce overdose deaths.” Another recently published report into prescription opioid use in Utah following the state’s legalization of medical marijuana found that the availability of legal cannabis both reduced opioid use by patients with chronic pain and helped drive down prescription overdose deaths statewide. Overall, results of the study indicated that “cannabis has a substantial role to play in pain management and the reduction of opioid use,” it said. President Donald Trump said in December that marijuana can “make people feel much better” and serve as a “substitute for addictive and potentially lethal opioid painkillers” as he issued an executive order to federally reschedule cannabis and promote access to CBD for therapeutic purposes. He clarified, however, that he personally has no interest in using marijuana himself. The post Medical Marijuana Helps People Stop Using Opioids, Sleeping Aids And Other Prescription Drugs, Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Texas voters strongly support legalizing medical marijuana yet are largely unaware of their own state’s existing program that provides limited access to cannabis for certain patients, according to a new poll. The survey by Fabrizio, Lee & Associates, which served as the chief pollster for President Donald Trump’s campaigns, found that 75 percent of Texas registered voters favor “legalized marijuana in Texas for medical use”—including 85 percent of Democrats, 63 percent of Republicans and 81 percent of independents. “Medical marijuana is very popular with Texas voters—not only do 3-in-4 voters support its use but majorities of each partisan group also support legalized medical marijuana,” the firm wrote in a polling memo. That said, only 11 percent of respondents said they have recently seen, read or heard anything about the Texas Compassionate Use Program (TCUP), which provides legal access to low-THC medical cannabis products for patients with a limited number of conditions and which lawmakers passed legislation to modestly expand last session. When told more about the program, three out of five voters say they are concerns about “delays and obstacles have slowed the expansion” of TCUP, which has resulted in “limiting access for patients who may benefit from medical marijuana.” That includes majorities of Democrats and independents and a bare plurality of Republicans. In response to a separate question, fifty-seven percent of voters agreed that “state leaders have moved too slowly in expanding and improving” the medical marijuana program—again with most Democrats and independents on board as well as a plurality of GOP voters. Earlier this month, Texas officials conditionally approved more new medical marijuana business licenses as part of a law that’s being implemented to expand the state’s cannabis program. In addition to increasing the number of dispensaries in the state, the law signed by Gov. Greg Abbbott (R) last year also expands the state’s list of medical marijuana qualifying conditions to include chronic pain, traumatic brain injury (TBI), Crohn’s disease and other inflammatory bowel diseases, while also allowing end-of-life patients in palliative or hospice care to use marijuana. When respondents were informed of the recent enactment the law to expand access, 62 percent said they favored the program—with majority support across party lines. The poll also found that voters are generally more likely to support lawmakers who support increasing medical marijuana access for patients and to have less favorable opinions of officials who are “dragging their feet and trying to stall the implementation” of the expanded program. “Registered voters in Texas support legalized marijuana for medical use and are virtually unaware of the state’s program for medical marijuana,” the polling memo says in a summary of the results. “For this reason, voters are supportive of TCUP after learning the program was expanded to certain qualifying conditions. Voters are concerned about delays or obstructions to TCUP and believe the implementation of the decade-old program has been too slow.” “Voters are more likely to support their legislator who supported expanding TCUP and are less likely to favor legislative leaders or the Governor’s agencies if they slow roll the implementation of TCUP,” it says, The poll involved interviews with 1,000 registered voters from April 1-2 and has a margin of error of ±3.1 percentage points. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The TCUP expansion and new poll results come as Texas officials are moving to implement new restrictions on hemp products, including a ban on THCA smokable hemp flowers that took effect last month but was later temporarily paused by a judge amid a legal challenge from the hemp industry. Last month, Texas voters approved a marijuana legalization question that appeared on the state’s Democratic primary ballot. A statewide poll released in February found that Texas voters don’t like how state leaders and lawmakers have handled marijuana and THC policy issues. In the survey, a plurality of voters (40 percent) said they disapprove of how their elected officials have approached the issue, according to the survey. Just 29 percent said they approve of how cannabis issues have been handled, while 31 percent said they didn’t have an opinion one way or another. A separate poll released last year found that a plurality of Texas voters want the state’s marijuana laws to be made “less strict.” And among the legislative items lawmakers considered during recent special sessions, voters say a proposal to address hemp regulations was among the least important. Meanwhile, the lieutenant governor and House speaker announced last month that the state will proceed with its own ibogaine research program after no drug companies submitted proposals meeting requirements and standards to receive state funds to begin clinical trials with the psychedelic under a recently enacted law. Read the full results of the Texas medical marijuana poll below: https://www.documentcloud.org/documents/28053853-texas-medical-marijuana-poll/ Image element courtesy of AnonMoos. The post Texas Voters Support Legal Medical Marijuana Access But Are Largely Unaware Of The State’s Existing Program, Poll Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A newly filed bipartisan bill in the U.S. Senate would effectively let states opt out of the federal recriminalization of hemp THC products that is set to be enacted later this year. Hemp derivatives with less than 0.3 percent delta-9 THC on a drug-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, Trump signed new legislation containing provisions that will redefine hemp in a way that advocates say stands to destroy the industry, making it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. Under the new Hemp Safety Enforcement Act—introduced on Thursday by Sens. Rand Paul (R-KY), Amy Klobuchar (D-MN) and Joni Ernst (R-IA)—states and Indian tribes could decide to continue regulating and allowing hemp THC products to be produced and sold in their jurisdictions despite the planned federal ban. The new restrictive policy will “wipe out the multi-billion-dollar industry, while depriving individuals of products they depend upon to improve sleep, relieve anxiety, and alleviate pain,” Paul said in a social media post. “My bill would protect thousands of jobs, family farms, and safe access for veterans and seniors.” “About half the states, including Kentucky, have already established their own regulatory rules for hemp: age limits, serving size caps, and testing requirements,” he said. “These state laws let farmers thrive while keeping products out of kids’ hands.” Big News on Hemp: Introducing the Hemp Safety Enforcement Act Congress's last-minute revival of hemp prohibition, included in last year's Continuing Appropriations Act, would ban most hemp products and wipe out the multi-billion-dollar industry, while depriving individuals of… — Senator Rand Paul (@SenRandPaul) April 16, 2026 The bill says that “a State or Indian tribe desiring to have primary regulatory authority over the production of hemp and hemp-derived cannabinoid products in the State or territory of the Indian tribe may submit” to the U.S. secretary of agriculture, “through the State department of agriculture (in consultation with the Governor and chief law enforcement officer of the State) or the Tribal government, as applicable, a notice that the State or Indian tribe elects not to be subject to” the impeding federal ban. In order for the opt-out to take effect, state or Indian tribe would also need to “implement a minimum age requirement for the purchase of hemp-derived cannabinoid products,” the bill, S.4315, says—without specifying what that age limit needs to be. The legislation would also allow interstate commerce between states and tribes that opt out of the broad national prohibition. “We can look out for public safety without trampling states’ rights or adult choice,” Paul said. “We’ve seen prohibition fail before. It fails miserably.” 3/ My Hemp Safety Enforcement Act creates an 'opt-out' so states can continue regulating hemp themselves, as long as they maintain a minimum age for purchase and keep the ban on dangerous synthetic cannabinoids that don’t naturally occur in the hemp plant. — Senator Rand Paul (@SenRandPaul) April 16, 2026 Earlier this week, Paul said in an online town hall meeting that the bill aims to avert what he called the “disaster” of the planned federal hemp product ban. The GOP senator noted that Klobuchar is a member of the Senate Agriculture Committee that is preparing the next version of the Farm Bill. “Our hope is that she can get a vote in committee to try to attach this to the Farm Bill,” Paul said of the standalone hemp relief bill. “We’re keeping our fingers crossed, but it’s difficult for those in business right now, because it’s a crop, it has to be planted, and if it’s going to be made illegal in November, farmers are wondering whether they should plant it this year.” 5/ We can look out for public safety without trampling states’ rights or adult choice. We’ve seen prohibition fail before. It fails miserably. Looking forward to bipartisan support to get this done.#HempSafetyEnforcementAct — Senator Rand Paul (@SenRandPaul) April 16, 2026 Jonathan Miller, general counsel of the U.S. Hemp Roundtable, told Marijuana Moment that the group is “deeply grateful” to the sponsors of the new legislation “for their steadfast continued leadership on behalf of the hemp industry.” He said Ernst’s joining “the pro-hemp team” is a “major development.” “Sen. Ernst is deeply respected for her agricultural experience,” Miller said. “Her participation is an important statement that U.S. farmers are deeply at risk if the impending ban goes into effect.” Eric Zipperle, co-founder and CEO of the Kentucky-based company Cornbread Hemp, told Marijuana Moment that the bill “gets it right.” “States are the microcosms of democracy, and Kentucky proves it. We already have a robust, functioning regulatory framework for hemp-derived THC—age verification, potency limits and retailer licensing,” he said. “Washington doesn’t need to reinvent the wheel. Let the states that have done the work keep doing it.” Paul had previously announced back in November of last year that his planned hemp reform bill could be filed within days, but that didn’t materialize at the time. Other lawmakers have introduced legislation to delay the scheduled recriminalization of hemp THC products, but those efforts have not gained traction with congressional leadership. Meanwhile, the Trump administration this month launched a new initiative to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows a certain amount of THC in products. Paul said in a social media post that his bill “preserves interstate commerce for legal products and is fully consistent with President Trump’s executive order expanding medical marijuana and CBD research.” Anti-marijuana organizations filed a lawsuit suit against the Medicare hemp coverage policy, and lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz recently filed a brief asking that the case be dismissed. Meanwhile, the White House Office of Management and Budget has been holding a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA also issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. As hemp products have become more popular with consumers, some large brands are attempting to get in on action. Major retailer Target, for example, is expanding its participation in the hemp-derived THC beverage market. Last year, the company began a pilot program involving sales of cannabis drinks at 10 select stores in Minnesota. That apparently went well, and now the company has obtained licenses from Minnesota regulators to sell lower-potency hemp edible products—including THC drinks—at all 72 of its stores in the state. Read the full text of the new Senate hemp bill below: https://www.documentcloud.org/documents/28054302-hemp-safety-enforcement-act/ The post States Could Opt Out Of Federal Hemp THC Product Ban Under New Bipartisan Senate Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Louisiana Senate has passed a bill to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin and ibogaine. The legislation from Sen. Patrick McMath (R) cleared the chamber, with new amendments, in a unanimous vote of 37-0 on Wednesday. “This concept, this new type of treatment, was brought to my attention by members who served as Navy SEALs and terror rescue men and saw combat and came home and struggled with with post-traumatic stress. And had it not been for this ibogaine treatment that they had to go down to Mexico to receive, they would not be here with us today,” McMath said ahead of the vote. “They would not be fathers. They would not be friends.” “The results, not only in post-traumatic stress, but also in substance abuse disorder and chronic depression are are overwhelming—over 90 percent success success rate when it comes to both heroin and alcohol dependency,” he said. “Seventeen veterans per day in this country commit suicide. For every combat death, there are five veterans that commit suicide when they come home. If we don’t try to remove some of the regulatory pathways for those folks who sacrificed so much to find peace, then shame on us.” The bill now heads to the House of Representatives for consideration. If the legislation is enacted into law, the psychedelics program would be overseen by the Louisiana Department of Health (LDH), which would be responsible for facilitating clinical trials involving substances that hold therapeutic potential. The bill says that eligible participants would include people with opioid use disorders, co-occurring substance use disorders and treatment-resistant neurological or mental health conditions. Any studies would need to go though the federal Food and Drug Administration (FDA) investigational drug approval process. Researchers would also need to be permitted by the Drug Enforcement Administration (DEA) to conduct trials involving the Schedule I controlled substances. Patients participating in the studies would need to go through mental and physical health screening, and researchers would also be required to develop processes that ensure safety and compliance, with adverse event reporting rules, training and licensing for therapists and policies for tracking and handling the psychedelics. There are also specific provisions in the bill (SB 43) concerning ibogaine, with academic institutions authorized to collaborate in the clinical trials to bolster FDA approval prospects to develop prescription drugs based on the psychedelic. Researchers would also be encouraged to collaborate with institutions in other states that have similar programs in place. If a drug is approved and developed as a result of the pilot program clinical trials, there would be a revenue sharing requirement, with 20 percent of the profits that would go to the state. Under an amendment previously adopted in committee, Louisiana would participate in a national consortium for ibogaine research and drug development. If an ibogaine therapy does gain FDA approval, revenue tied to the intellectual property rights of that drug would go to the consortium (except for the 20 percent specifically earmarked for Louisiana). The new amendments the sponsor offered on the floor “make some changes to align the clinical study procedures with best practices” and “remove the fiscal impact to the department,” McMath said. Last year, the senator also sponsored a resolution approved by the full chamber that called for the establishment of a task force to study and make recommendations on the potential therapeutic benefits of psychedelics for veterans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Separately, the Senate also recently passed a bill to let patients with terminal and irreversible conditions use medical marijuana in hospitals. Meanwhile in the state, another Louisiana lawmaker recently introduced a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. Rep. Candace Newell (D)—who has long championed legislation to end cannabis criminalization and filed a similar legal marijuana pilot program measure last session—is sponsoring what’s titled the “Adult-Use Cannabis Pilot Program Regulation and Enforcement Act.” Getting the bill across the finish line could prove complicated in the conservative legislature, however. Newell’s earlier version of the pilot program legislation didn’t advance to enactment last year, and lawmakers that session also rejected other marijuana reform proposals such as one that would have established a tax system to prepare the eventual legalization of adult-use cannabis. Image courtesy of CostaPPR. The post Louisiana Senate Passes Bill To Create Psychedelic Therapy Pilot Program Funded By Opioid Settlement Dollars appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

One of the senators leading the fight to legalize marijuana in Congress joked that the federal government might need to step in and enact restrictions on a more addictive substance: french fries from McDonald’s. Sen. Cory Booker (D-NJ), who has sponsored several bills to remove cannabis from the Controlled Substances Act (CSA), said that “I am the leader in the Senate for descheduling marijuana, but we should schedule McDonald’s french fries.” “I don’t know what they put on them,” he said. “I think it is an illegal substance.” The senator’s comments came at an event late last month where he was promoting his new book, “Stand.” Booker was telling a story about his relationship with his driver, who has been with him since he served as mayor of Newark, New Jersey. “We’ve been in the car together for, God, 20 years, and we don’t have to speak to each other. He can just look in the rearview mirror and sense that I’m in one of those moments where I’ve got to do work, I got to read documents, whatever,” Booker said. “And so he, as we get ready to pass this McDonald’s, he looks in the rearview mirror and immediately, quickly, lurches into the drive through because he, using his telepathic powers, looked in the rearview mirror and saw the look of shame on my face, and he knew that I needed—physical addiction here—I needed some McDonald’s french fries.” After ordering two servings of fries “with shame in my voice,” the senator said, he was “holding them like I’m from that movie, Lord of the Rings. My precious.” This is not the first time the senator has compared the safety and legal status of marijuana and fast food. Back in 2019 when he was a candidate for the Democratic presidential nomination, he shared an anecdote about visiting a Burger King where he loaded up on vegan burgers and fries, saying, similarly, that “I’m the guy that believes we should deschedule marijuana on the federal level, but maybe we should schedule those fries because they are very addictive.” While Booker says he is vegan, it should be noted that the french fries McDonald’s serves in the U.S. contain natural beef flavor. Burger King’s fries contain no animal products, however. When it comes to cannabis policy, Booker told Marijuana Moment in January that it’s “too early to tell” what the implications of President Donald Trump’s executive order directing the Department of Justice to expedite the process of moving cannabis from Schedule I of the CSA to Schedule III will be—saying that while there are “things that look promising” about it, he is “very concerned about where the DOJ will land.” It’s now been almost four months since the president issued that order, with no formal update from the Justice Department. Booker added in the interview with Marijuana Moment that the administrative rescheduling move, if it is finalized, could potentially open to the door to advancing additional cannabis reforms in Congress such as the Secure and Fair Enforcement Regulation Banking Act (SAFER) Banking Act, which would make it easier for marijuana businesses to access financial services. “As a legislator, for me, that might get us an opening to some of the things that are stalled in Congress,” he said. “But ultimately that’s where I feel more comfortable, so that no matter who the president is, we have a structure that works to end the injustices and to liberate, frankly, an industry that has been severely hamstrung.” The senator, who at one point threatened to block the advancement of industry-focused banking legislation if it did not include more equity-focused provisions, said that he’s since “been able to get into SAFER some of the elements that are important to me to be able to support it.” Booker has also joined other Democratic senators in sponsoring legislation to federally legalize marijuana by descheduling it from the CSA. The post Marijuana Is Safer Than McDonald’s French Fries, Cory Booker Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

New bipartisan federal hemp bill soon; VA gov talks marijuana amendments; Cannabis arrest stories requested; “One Plant” cannabis strategy op-ed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW President Donald Trump is reportedly considering issuing an executive order as soon as this week aimed at boosting research on the benefits and safety of the psychedelic ibogaine, a move that comes nearly four months since the president’s marijuana rescheduling order that still hasn’t been fulfilled. Sen. Rand Paul (R-KY) said he and Sen. Amy Klobuchar (D-MN) are filing a bill to let states opt out of the federal recriminalization of hemp THC products that’s set to take effect later this year. “It’s good for Kentucky farmers. It’s a cash crop, kind of like tobacco…and I think we ought to expand it.” Virginia Gov. Abigail Spanberger (D) defended her significant amendments to a bill to legalize recreational marijuana sales by saying she proposed them after speaking with governors of other states with legal cannabis markets. “Every one of them said some version of make sure you get it right the first time and don’t rush it because there will be things that come up.” The Marijuana Policy Project is asking people to share their stories about being arrested over cannabis for possible inclusion in a new report the organization is preparing to publish detailing “the true impact of the ongoing scourge of prohibition.” Jason Leisey of Emerald Tea Supply Co. argues in a new Marijuana Moment op-ed that because hemp and marijuana are both the same plant, they need to be held to the same standards. “If the loophole persists, that trust erodes. Not because the hemp farmers are bad people. But because a system that applies rigorous standards to one channel and none to another will eventually produce a failure that damages everyone.” Missouri hemp industry leaders delivered thousands of letters asking Gov. Mike Kehoe (R) to veto a bill that would ban intoxicating hemp THC products in the state—even if planned federal restrictions are delayed or reversed. / FEDERAL The U.S. Sentencing Commission adopted amendments to federal sentencing guidelines, including for drug offenses. Former Sen. Mitt Romney (R-UT) said marijuana use is “really dangerous to the future of our civilization,” citing the opinion of healthcare providers who think it is “the biggest single source of the mental crisis that we’re having in the country.” / STATES A Virginia senator said she is “exploring all available legislative options” for addressing Gov. Abigail Spanberger’s (D) proposed amendments to her recreational marijuana sales legalization bill. An Ohio judge temporarily paused newly enacted cannabis restrictions. Missouri officials posted a warning about a drug trafficking scam targeting doctors. Minnesota regulators sent a reminder about the upcoming April 30 deadline to apply for hemp growing and processing licenses. Utah regulators published an annual report on the medical cannabis program. Massachusetts regulators published new public education videos about marijuana ahead of 4/20. The Colorado Retail Marijuana Public Health Advisory Committee will meet on Monday. Oregon regulators will host psilocybin services listening sessions on May 6 and 8. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL A Western Australia lawmaker criticized the government for lack of action to protect medical cannabis patients from driving under the influence charges. / SCIENCE & HEALTH A review concluded that “cannabis sativa phytochemicals emerge as promising molecular entities with the potential to reshape integrative oncology.” A review concluded that “MDMA-assisted therapy results in short-term decreases in PTSD symptoms across studies to date, though more trials are needed.” / ADVOCACY, OPINION & ANALYSIS The Lancet editorial board is calling for an end to the war on drugs. / BUSINESS Curaleaf Holdings, Inc. announced a share repurchase program. TerrAscend Corp. has a new chief financial officer. Sun Extractions workers in Hamilton, New Jersey voted to unionize with United Food and Commercial Workers Local 360. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Trump is planning a psychedelics executive order (Newsletter: April 17, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

My small business is partially woman-owned, and growing my reach is a constant challenge. I've found email marketing tough, but connecting with people is key. When I feel overwhelmed by marketing strategies, I sometimes Steal Brainrot and watch silly videos to recharge. It sounds crazy, but it helps! I would love to lead a Q&A for the Gardener's Club, sharing what I've learned about connecting with customers and implementing equality policies within my organization.

A Republican senator said he expects bipartisan legislation to be introduced in Congress this week to avert what he called the “disaster” of the federal recriminalization of hemp THC products that is set to be enacted later this year. Sen. Rand Paul (R-KY) said in an online town hall meeting he hosted on Tuesday that hemp has “become a multi-billion-dollar industry” since products with less than 0.3 percent delta-9 THC on a drug-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, Trump signed new legislation containing provisions that will redefine hemp in a way that advocates say stands to destroy the industry, making it so only products with 0.4 milligrams of total THC per container will remain legal. “I lament the government’s trying to destroy this industry now, but I’m doing everything I can and working across the aisle with a Democrat senator to try to say that if your state has decided to regulate hemp, then the state law would supersede the federal law, which is kind of really the way it’d be ought to be,” Paul said. The GOP senator said he and Sen. Amy Klobuchar (D-MN) plan to file legislation “that I think is going to be introduced this week” to give states a way around the broad federal prohibition that’s scheduled to take effect in November. I’m working across the aisle to protect HEMP — a multi-billion dollar, legal industry supporting farmers in Kentucky and across America. Washington shouldn’t destroy what states are managing successfully. Let’s keep this industry strong. pic.twitter.com/hXgTRqHvmj — Senator Rand Paul (@SenRandPaul) April 16, 2026 “She’s on the Agricultural Committee, and they do the Farm Bill. Our hope is that she can get a vote in committee to try to attach this to the Farm Bill,” Paul said of the forthcoming standalone hemp relief bill. “We’re keeping our fingers crossed, but it’s difficult for those in business right now, because it’s a crop, it has to be planted, and if it’s going to be made illegal in November, farmers are wondering whether they should plant it this year.” The text of the Paul-Klobuchar hemp bill has not yet been made publicly available, but a source told Marijuana Moment on Thursday that its provisions would effectively allow states to opt out of the federal hemp THC recriminalization policy and conduct interstate commerce between themselves. Paul, for his part, said in the town hall meeting this week that “Kentucky has a successful hemp industry.” “There are new startup companies now. They’ve expanded to the tune of millions of dollars,” he said. “And it’s been good for Kentucky. It’s good for Kentucky farmers. It’s a cash crop, kind of like tobacco—not as big as tobacco, but kind of like tobacco as a cash crop—and I think we ought to expand it.” Watch Paul’s full hemp comments, beginning around 41:50 into the video below: Paul had previously said back in November of last year that his planned hemp reform bill could be filed within days, but that didn’t materialize. Other lawmakers have introduced legislation to delay the scheduled recriminalization of hemp THC products, but those efforts have not gained traction with congressional leadership. Meanwhile, the Trump administration this month launched a new initiative to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows a certain amount of THC in products. Anti-marijuana organizations filed a lawsuit suit against the Medicare hemp coverage policy, and lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz recently filed a brief asking that the case be dismissed. Meanwhile, the White House Office of Management and Budget has been holding a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA also issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. As hemp products have become more popular with consumers, some large brands are attempting to get in on action. Major retailer Target, for example, is expanding its participation in the hemp-derived THC beverage market. Last year, the company began a pilot program involving sales of cannabis drinks at 10 select stores in Minnesota. That apparently went well, and now the company has obtained licenses from Minnesota regulators to sell lower-potency hemp edible products—including THC drinks—at all 72 of its stores in the state. The post Bipartisan Bill To Save Hemp Industry From Renewed Federal Criminalization Could Be Filed This Week, Rand Paul Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

President Donald Trump is reportedly planning to issue an executive order as soon as this week signaling the administration’s willingness to explore the therapeutic benefits and safety of the psychedelic substance ibogaine. CBS News reported on Thursday that while the administration doesn’t plan to reschedule the psychedelic out of Schedule I of the Controlled Substances Act (CSA) at this time, the move is “meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.” The outlet said that while officials are still in the process of drafting the executive order’s provisions, the aim is to help determine whether ibogaine is what one source described as “snake oil” or is instead a legitimate treatment. Citing two sources, CBS reported that the president’s move could come within days. Early research and experience indicates that ibogaine can help people suffering with post-traumatic stress disorder, traumatic brain injuries and drug addiction. Lawmakers in a number of states have passed legislation to support clinical trials with the aim of developing ibogaine into a legal medication with approval from the Food and Drug Administration (FDA). Texas officials, for example, recently announced that the state will move ahead with launching its own research program on the psychedelic after the they couldn’t find a company to lead a consortium on the issue under a bill enacted last year. The reportedly planned federal move on ibogaine comes nearly four months after Trump issued an executive order directing the Department of Justice to completed the process of moving marijuana from Schedule I of the CSA to Schedule III “in the most expeditious manner”—though that still hasn’t happened. Meanwhile, Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.” In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.” “Everybody in my agency…is very anxious to get a rule out there that will allow these kind of studies and will allow access under therapeutic settings, particularly [for] the military soldiers who have suffered these injuries to get access to these products,” the HHS secretary said. “We’re working through that process now. We’re all working on it and trying to make it happen.” “I think that we’re going to get it done,” he said. Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” VA Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access. Bipartisan congressional lawmakers introduced legislation this session to provide $30 million in funding annually to establish psychedelic-focused “centers for excellence” at U.S. Department of Veterans Affairs (VA) facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine. Former U.S. House Speaker Newt Gingrich (R-GA) has said ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options. Photo courtesy of Flickr/Scamperdale. The post Trump Plans To Sign Executive Order On The Psychedelic Ibogaine As Soon As This Week, Report Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“If the loophole persists, that trust erodes. Not because the hemp farmers are bad people. But because a system that applies rigorous standards to one channel and none to another will eventually produce a failure that damages everyone.” By Jason Leisey, Emerald Tea Supply Co. I spent years in institutional finance trading macro derivatives before I built a licensed cannabis dispensary in New Jersey. I understand how regulatory arbitrage works—how a legal category distinction, rather than any meaningful difference in the underlying asset, can create a two-tier market where one side bears all the cost and the other captures all the margin. That is exactly what the hemp loophole in federal and state laws has produced. A recent Marijuana Moment op-ed authored by hemp farmer John Grady, eloquent as it is, argues for keeping it that way. Let me be clear about where I stand: I am not anti-hemp. I am not lobbying for marijuana to win a market war. I am pro-regulation of THC—full stop—regardless of which plant it came from. That distinction is the foundation of everything that follows. First: Hemp And Cannabis Are The Same Plant Before we can talk policy, we need to talk biology—because the entire regulatory debate rests on a distinction that does not exist in nature. Hemp and cannabis are the same species: Cannabis sativa L. The difference between them isn’t visible in a field, detectable in a lab, or encoded in genetics. It exists exclusively in a law book. Since the 2018 Farm Bill, federal law has defined “hemp” as any cannabis plant containing 0.3 percent or less Delta-9 THC by dry weight. Everything above that threshold is legally “marijuana.” Same plant. Same molecule. Different regulatory universe depending on a number. Think of it like moonshine and bourbon. Both are distilled from grain. Both are chemically ethanol. Nobody argues that moonshine should be sold unregulated at a farmers market simply because it came from a different still—or because the distiller loves the craft. The intoxicating molecule is the same. The public safety obligation is the same. The source doesn’t change the standard. That is exactly what has happened with hemp and cannabis. And in 2026, the practical consequence of that category error has become impossible to ignore. The Molecule Doesn’t Care About The Label The central argument in Grady’s Marijuana Moment op-ed is that hemp and marijuana are the same plant, so they should be treated differently by regulators. Read that sentence again. He uses biological unity to argue for regulatory fragmentation. That is not a coherent position. A hemp-derived delta-9 THC gummy and a dispensary-sold THC gummy produce similar physiological effects in the person who consumes them. Grady’s “Hemporium” model asks consumers to trust that the unregulated version is just as safe as the one subject to mandatory third-party testing, seed-to-sale tracking and state-certified lab verification for heavy metals, pesticides and residual solvents. That is not consumer protection. That is a market positioning argument dressed in the language of one. If the plants are the same, the rules must be the same. The molecule doesn’t care about the label. Neither should the law. Regulation Is A Safety Floor, Not A Barrier Grady frames the licensed dispensary channel as a “market entry barrier.” He’s right that it is—in the same way that an Federal Aviation Administration license is a barrier to flying a commercial aircraft. A private pilot who loves the sky and has logged thousands of hours still cannot fly a 737 without certification, because the stakes of failure extend far beyond the cockpit. At Emerald Tea Supply Co., our “barriers” include state-mandated lab testing for every product on our shelves, strict age verification with no exceptions, zoning requirements that respect school buffers and community standards, seed-to-sale tracking that ensures zero diversion to minors and social equity contributions built into our licensing structure. These aren’t obstacles we resent. They are the infrastructure of trust that earned us the right to operate—and that protects the consumers who walk through our door. When Grady argues for selling intoxicating THC products outside that framework, he is not arguing for a level playing field. He is arguing for the right to benefit from the public trust that the regulated market built, without paying the price of building it. The True Cost Of The Loophole There is a real economic injury here that goes beyond competitive disadvantage, and it has a number attached to it. Because cannabis remains federally scheduled, licensed dispensaries are subject to IRS Section 280E—a tax provision that prohibits us from deducting ordinary business expenses. Rent, payroll, utilities: none of it deductible. The result is that cannabis operators routinely face effective federal tax rates of 70 percent or higher on gross profit, while filing like any other American business is simply unavailable to us. Meanwhile, hemp retailers selling chemically identical intoxicating products file as ordinary retail. Same molecule. Radically different tax treatment. Add state excise taxes that fund social equity programs and community reinvestment, compliance overhead, licensing fees and mandatory security infrastructure—and the gap becomes structural. When a hemp shop undercuts my prices on a product that produces the same effect as mine, they aren’t competing on craft or quality. They are competing on a government-granted exemption from the rules I built my business around. That is regulatory arbitrage. The consumers who pay the price when that system fails are the same veterans, patients and community members both Grady and I claim to serve. The “One Plant” Logic Cuts Against Grady’s Hemp Argument Grady invokes Steve DeAngelo and the One Plant Alliance approvingly. He agrees, philosophically, that the marijuana plant is the hemp plant. Then he argues for two separate regulatory tracks based on which side of an arbitrary federal definition a product falls on. The One Plant Alliance’s actual position—age verification, testing and labeling applied equally across every sector of the plant—is precisely what I am advocating. Grady has adopted the branding while rejecting the substance. If you believe in One Plant, you believe in One Rule. Everything else is marketing. What’s Actually At Stake I support federal legislation that creates a unified, source-agnostic regulatory standard for all intoxicating cannabinoid products. A per-serving THC limit, mandatory age-gating and third-party testing requirements—enforced equally whether the product comes from a hemp farm in Missouri or a licensed cultivator in New Jersey—would solve the problem Grady says he wants to solve. But I want to end with what Grady ended with: the human cost. He mourns what is being lost in the hemp industry. I understand that grief. I also know what is at stake on the other side of the ledger. Every veteran who walks into my dispensary looking for a tested, traceable product to manage pain or PTSD is making a trust decision. They are trusting that what is on the label is what is in the product. That trust was built by the regulated market—by operators who submitted to oversight, absorbed the tax burden and did the compliance work that nobody outside this industry ever sees. If the loophole persists, that trust erodes. Not because the hemp farmers are bad people. But because a system that applies rigorous standards to one channel and none to another will eventually produce a failure that damages everyone—and the patients and veterans who finally found something that works will be left wondering who to believe. One plant. One rule. That is not consolidation. That is integrity. And it is the only foundation this industry can build on. Jason Leisey is a combat veteran of the Iraq War, Columbia MBA and CEO of Emerald Tea Supply Co., a licensed cannabis dispensary and delivery operation in Bloomfield, New Jersey. Photo courtesy of Brendan Cleak. The post When It Comes To Marijuana And Hemp, If You Believe In One Plant You Need To Believe In One Rule (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I initially thought LOWD was just an ordinary cannabis company, but it turns out they're actually connected to Escape Tsunami for Brainrots game? I saw this connection while browsing news on the subway, and I was a bit confused, but thinking about it carefully, it's actually quite interesting.

“It would effectively eliminate an entire industry in Missouri—the hemp industry—regardless of any federal change in legislation.” By Rebecca Rivas, Missouri Independenta Gov. Mike Kehoe’s (R) office received 10,000 handwritten letters Tuesday asking him to veto a Missouri bill that would impose a statewide ban on intoxicating hemp products. The letters, gathered in just 10 days, came from small-business owners, farmers and customers across Missouri who say the legislation could wipe out the state’s hemp industry—even if Congress ultimately pulls back from its own ban set to go into effect on November 12. Opponents’ main concern is the proposed hemp ban could make Missouri’s guidelines more restrictive than the provision Congress included in a federal spending package signed by the president. “These are voices of Missourians that want their voices to be heard,” Jay Patel, president of Missouri Hemp Trade Association, said during a press conference on the Missouri Capitol steps Tuesday. “The bill sits on the governor’s desk, and if signed, it would effectively eliminate an entire industry in Missouri—the hemp industry—regardless of any federal change in legislation or extensions that may occur.” The legislation, sponsored by state Rep. Dave Hinman (R) of O’Fallon, comes amidst uncertainty on where the federal government will finally land on regulations for intoxicating hemp products. There’s a possibility Congress could delay the implementation of the ban or set different regulations for certain products, such as beverages or CBD products with a small amount of THC. Under Missouri’s bill, all intoxicating hemp products would be taken off the shelves starting November 12—including THC seltzers currently sold in bars and grocery stores—just like they will nationwide. But if Congress reverses course and decides to allow the sale of these products, Missouri would only permit them to be sold in licensed marijuana dispensaries. And if Congress chooses to delay the ban, Missouri would still ban all products, except for intoxicating beverages. Kehoe’s office was expecting to receive the bill on Tuesday, his spokeswoman Gabrielle Picard said, and he’ll have 15 days from when it officially lands on his desk to sign or veto the bill. She said it’s the first time this year the governor’s received such a large amount of handwritten letters in opposition to a bill and is “somewhat unique” in general. The governor is still reviewing the bill and has not made a decision, Picard said. Kehoe has publicly expressed his support for aligning the state with the federal ban. Missouri Attorney General Catherine Hanaway (R) has also expressed support for the bill. Since November, she’s sent 33 cease and desist letters, demanding that businesses stop selling intoxicating hemp products. Intoxicating hemp products with as much as 1,000 mg of THC are being sold in smoke shops—outside of Missouri’s licensed marijuana dispensaries—and they aren’t regulated by any government agency. Missouri lawmakers have failed to pass legislation regulating these products since 2023. Adding to the complicated regulatory environment, President Donald Trump signed an executive order in December ordering his administration to work with Congress to develop a framework that permits full-spectrum CBD products. Under Trump’s leadership, the Centers for Medicare & Medicaid Services rolled out an initiative on April 1 that could cover $500 per year worth of hemp-derived THC of 3mg per serving and CBD products for eligible users. The products under this program would be illegal nationwide if Congress doesn’t change the language in the upcoming ban. That’s why hemp association leaders feel the CBD program rollout gives a strong indication the language will change. But under the bill before Kehoe, Missouri would not allow patients to participate in this program, said Brian Riegel, owner of South Point Hemp, who is among the Missouri business owners developing products that would meet the requirements of the CBD program. “I feel like I’m getting left behind,” Riegel said. “There’s some other manufacturers in other states who aren’t doing this right now [of the veto letter campaign]. They’re working on this new Medicare initiative that’s launching fast. I feel like if you’re not first, you’re last.” Hinman told The Independent that wasn’t the bill he was hoping to pass this year. He was hoping to continue what he worked on for 10 months last year—bringing hemp business owners together to propose a regulatory framework outside of the marijuana rules. Restricting the products to only be sold in cannabis dispensaries was also not his preference, he said, but it’s the regulatory framework the state already has in place. His original language stated Missouri would delay its ban if the federal government did, but he said that would unintentionally leave the products unregulated in the state indefinitely. All the pending bill does is, he said, codify the federal language and allows Missouri to use local police and local prosecutors to enforce the federal ban. “If this bill passes or if the governor decides to veto it, it doesn’t matter,” Hinman said, “because their businesses are still going to be gone. The federal government is the one who has come out and said as of November 12, they aren’t going to be in business anymore.” This story was first published by Missouri Independent. The post Missouri Hemp Businesses Ask Governor To Veto Bill That Would ‘Eliminate’ The Industry appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I stumbled upon the Tokeativity Workshop at Project Object, which is a quirky Portland spot. Elly Blue’s talk on book publishing and her work with pokepath really caught my eye-how does she balance all that?

As the unofficial marijuana holiday know as 4/20 approaches, a leading pro-legalization organization is asking people to share their personal stories about being arrested for cannabis, saying that doing so can help shine a spotlight on “the true impact of the ongoing scourge of prohibition.” The Marijuana Policy Project (MPP) said in an email alert to its supporters that the organization is preparing to release a new report on cannabis arrests and that it is “vitally important” that the document not just compile raw data on enforcement but also “include the real human stories that illustrate the harmful impact that prohibition and criminalization have on individuals, families, and communities.” The group’s email directs supporters to an online form where they can enter details about their cannabis-related law enforcement encounters and specify whether or not they are comfortable having their full names associated with their stories in MPP’s report. “Consider including details on what happened during and after the arrest(s), and how prohibition and criminalization have impacted your life,” the form prompts. As 4/20 approaches, we’re asking supporters who have been arrested for cannabis to share your story and help illustrate the true impact of the ongoing scourge of prohibition. https://t.co/kbnL02d8mX — Marijuana Policy Project (@MarijuanaPolicy) April 9, 2026 MPP is also inviting people who haven’t been arrested themselves to share details about incidents involving their friends and loved ones. “While cannabis arrests have been in decline nationally in recent years, there are still more than 200,000 arrests every year, which result in trauma, disruption, and derailed lives,” the organization’s email to supporters says. Data released by the Federal Bureau of Investigation late last year show that nearly 188,000 people were arrested over marijuana possession in the U.S. in 2024. Another 16,000 people were booked for allegedly selling or growing cannabis that year. Of all drug possession arrests in the country, 27 percent were for marijuana—more than for any other specifically listed substance. An analysis of the data by the National Organization for the Reform of Marijuana Laws (NORML) concluded that marijuana arrests are driving the overall war on drugs in states where cannabis remains illegal. The organization focused on 14 states in particular. In five of those states (Idaho, Iowa, Louisiana, Nebraska and Wisconsin), marijuana accounted for more than 50 percent of total drug-related arrests last year. For the other nine states (Alabama, Georgia, Indiana, Kansas, Mississippi, North Dakota, South Carolina, Utah and Wyoming), cannabis constituted a plurality of more than 40 percent of drug-related arrests. Notably, the FBI data, which are compiled from submissions to the agency by local and state law enforcement, show that more than 97 percent of cannabis arrests in Alabama, Nebraska, North Dakota, South Dakota, Texas, Utah and Wyoming were over possession, rather than trafficking or sales. NORML, meanwhile, is asking cannabis consumers to take a survey about the freedoms (or lack thereof) that they experience where they live. The survey is “designed to capture real-time sentiment from cannabis consumers across the United States and beyond, offering a snapshot of how individuals experience cannabis policy in their daily lives,” the group said. The post Marijuana Activist Group Asks People To Share Their Arrest Stories To Show The ‘True Impact’ Of Criminalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The governor of Virginia is responding to criticism of amendments she is proposing a bill to legalize recreational marijuana sales by saying the suggested changed came after she spoke to the leaders of other states that have already implemented adult-use cannabis markets. Gov. Abigail Spanberger (D) told local news outlets on Tuesday that the message she got from governors of other states is that “across the board, the top priority that people continue to put forth is do it methodically—because you have to do it right the first time.” “I’ve spent a lot of time talking to governors and folks from other states about those who do have a legalized recreational cannabis market, retail market,” the governor said. “Every one of them said some version of, ‘Make sure you get it right the first time and don’t rush it because there will be things that come up.’” The local news reports did not say whether Spanberger specified which other governors she spoke to about cannabis, and a spokesperson in her office did respond to Marijuana Moment’s request for clarification. On Monday, Spanberger proposed amendments to the cannabis commerce legalization measure—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The move sparked backlash not just from marijuana reform advocates but also from the sponsors of the legislation, who said the governor’s proposal “creates a less accessible legal marketplace” and “represents a significant departure from the framework passed by the General Assembly, raising serious concerns about fairness, access and public safety.” The governor, for her part, told WRIC-TV that “my goal is to make sure that there’s great clarity both in implementation and in the ending retail market that we end up with.” She also told Virginia Scope that her move was intended to “clearly define what a legal market is.” “It’s about making very clear that while we have a legal recreational marijuana market, or we are moving towards a retail recreational marijuana market, that it’s still clear that there are certain things that continue to be illegal,” she said. Gov. Spanberger told me she talked to leaders in other states where a retail market for weed already exists and the number one thing she heard is implement it methodically. Read more from my interview with the gov and the pushback from the bill’s sponsors. https://t.co/y30eMCQMgU — Brandon Jarvis (@Jaaavis) April 15, 2026 Here are the other key details of the cannabis bills—SB 542 and HB 642—as approved by lawmakers and with the governor’s suggested amendments: Lawmakers voted to allow adults to be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That represents an increase from the limit in current law of 1 ounce. The governor, however, wants the amount increased to only 2 ounces. Under the legislature’s plan, legal sales could begin on January 1, 2027, but the governor is proposing to push that back to July 1, 2027. Lawmakers voted to impose an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set an additional local tax of up to 3.5 percent. The governor’s plan is largely the same, though it would increase the excise tax to 8 percent starting on July 1, 2029. Under the legislation as approved by lawmakers, revenue would be distributed to the Cannabis Equity Reinvestment Fund (30 percent), early childhood education (40 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The governor, however, wants to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” The Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, and would also take on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. Local governments could not opt out of allowing marijuana businesses to operate in their area. Delivery services would be allowed. Serving sizes would be capped at 10 milligrams THC, with no more than 100 mg THC per package. The governor is proposing to make public marijuana use a class 4 criminal misdemeanor instead of civil violation punishable by a $25 fine as under current law. She also wants to make possessing cannabis by people under the age of 21 a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Illegally selling or distributing 50 pounds or more of marijuana would be a class 2 felony punishable by life in prison. The governor is seeking to eliminate support for the Cannabis Equity Reinvestment Fund. Existing medical cannabis operators could enter the adult-use market if they pay a licensing conversion fee that is set at $10 million. Cannabis businesses would have to establish labor peace agreements with workers. As passed by lawmakers, the bill would have directed a legislative commission to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations, but the governor is proposing to remove that language. The legislature is set to reconvene to address the governor’s proposal on April 22. Meanwhile, Spanberger also suggested significant amendments to separate legislation that would provide resentencing relief to people with prior marijuana convictions. Separately, the governor signed several other reform bills this week—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Governor Says Marijuana Bill Amendments Came After Speaking To Colleagues In Other States That Have Legalized appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

MD gov signs medical marijuana for animals bill; PA legalization budget vote; VA marijuana resentencing amendments; FDA hemp CBD memo op-ed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Internal Revenue Service said in a new Federal Register filing that marijuana industry workers are not currently eligible under the “No Tax on Tips” law signed by President Donald Trump to write off any gratuities they receive—but that it could change if cannabis is federally legalized. Maryland Gov. Wes Moore (D) signed legislation to provide legal protections for veterinarians who recommend medical cannabis for animals, making it so they can’t be punished for it by the State Board of Veterinary Medical Examiners. The Pennsylvania House of Representatives passed Gov. Josh Shapiro’s (D) budget plan that includes expected revenue from recreational marijuana sales, which haven’t yet been legalized in the state. Virginia Del. Rozia Henson, Jr. (D) criticized Gov. Abigail Spanberger’s (D) proposed amendment to scale back his marijuana resentencing relief bill—saying it would let people “fall through the cracks simply because they lacked a lawyer or did not know to ask.” “The amendment shifts that entire burden onto individuals navigating incarceration or active supervision; often without the information or resources to file a petition on their own.” Thomas Winstanley of Edibles.com argues in a new Marijuana Moment op-ed the Food and Drug Administration’s recent hemp CBD enforcement memo is “encouraging” but “falls short of a comprehensive solution.” “Only Congress can provide the clarity this market requires.” The Rhode Island Cannabis Control Commission filed an appeal of a federal court ruling blocking the state’s marijuana business licensing process amid a challenge to residency requirements. / FEDERAL Supreme Court Justice Sonia Sotomayor discussed changing principles of Fourth Amendment law as technology changes, such as when law enforcement can measure heat being generated in a home “commensurate with marijuana growing underneath the roof.” / STATES A Pennsylvania senator is again calling on the House of Representatives to pass his marijuana legalization legislation rather than first advancing it through the committee he chairs. Colorado regulators sent a health and safety advisory about marijuana products with pesticides above acceptable levels. Ohio regulators filed changes to marijuana tax rules. Missouri regulators are expanding an initiative to identify verified marijuana dispensaries. New Jersey regulators posted updated marijuana sales and revenue data. California regulators sent updates about various cannabis issues. Oregon regulators will consider a marijuana business violation stipulated settlement agreement on Thursday. The Rhode Island Cannabis Control Commission will meet on Friday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Ireland’s health minister appointed an official to lead a review of the country’s medical cannabis program. / SCIENCE & HEALTH A study indicated that “phenolic-rich fractions from cannabis seeds represent promising natural ingredients for cosmetic formulations targeting oxidative stress, skin aging, hyperpigmentation, and cutaneous inflammation.” A review concluded that “psilocybin-assisted-psychotherapy was found to have a primarily positive effect on spiritual well-being and quality of life.” / ADVOCACY, OPINION & ANALYSIS The Welsh Liberal Democrats adopted a resolution supporting legal protections for medical cannabis patients. / BUSINESS Tilray Brands, Inc. acquired Lyphe Group. Aurora Cannabis Inc. acquired Safari Flower Company. Organigram Global Inc. closed its acquisition of Sanity Group. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Brian Shamblen. The post IRS addresses cannabis industry worker tips (Newsletter: April 16, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net